Health Care·Biotechnology·$5.8B
CG Oncology Inc is a biotechnology company focused on developing innovative therapies for cancer treatment. As part of the health care sector, its advancements could significantly impact patient outcomes and the overall market for oncology treatments.
Earnings Per Share (EPS)
EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor.
Revenue Growth
While revenue estimates are not available, any growth in revenue would signal strong demand for CG Oncology's products.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
29%
Avg EPS Surprise
-29.65%
Avg Stock Reaction
+0.62%
In Q4 2025, CG Oncology reported an EPS of -$2.08, which was significantly below expectations. Despite this, the stock rose by 4.79% the following day, indicating some investor optimism.
Management Promises & Guidance
Overall, expectations for CG Oncology's upcoming earnings are mixed, with no analyst estimates available to guide sentiment. Investors are likely looking for signs of recovery after recent earnings misses.
Bull Case
If CG Oncology can show improvement in EPS and provide positive updates on clinical trials, it may restore investor confidence and drive the stock higher.
Bear Case
Conversely, if the company continues to report larger-than-expected losses and lacks clear guidance on future revenue, it could lead to further declines in stock price.
Earnings Per Share (EPS)
N/AEPS is a key indicator of the company's profitability and financial health, which investors will closely monitor.
Revenue Growth
N/AWhile revenue estimates are not available, any growth in revenue would signal strong demand for CG Oncology's products.
Clinical Trial Progress
N/AUpdates on clinical trials can indicate the potential success of their therapies and future revenue streams.
The print will turn on these two things.
Q1
What is the updated EPS figure for Q1-2026?
The EPS figure will be crucial in assessing the company's financial health and ability to manage costs.
Q2
What progress has been made in ongoing clinical trials?
Updates on clinical trials can significantly influence investor sentiment and expectations for future revenue.
Why consensus could be wrong
The market may be underestimating the potential for CG Oncology's clinical trials to yield positive results, which could lead to a quicker path to profitability than anticipated.
Supporting Evidence
Recent stock movements suggest that investors are still optimistic despite poor earnings.
The company's focus on innovative cancer treatments may lead to unexpected breakthroughs.
Historical patterns show that even after misses, stocks can rebound if future prospects appear strong.
Key Risk
If clinical trial results show significant promise, it could shift investor sentiment dramatically.
Pre-commit to what would confirm each case.
This quarter's results will be pivotal in determining whether CG Oncology can stabilize its financial performance and regain investor confidence.
Bull Confirmed If
A reduction in EPS losses to below -$1.50 would indicate improved operational efficiency.
Bear Confirmed If
If EPS exceeds -$2.00, it may signal ongoing financial struggles.
Implied Move
±N/A
There is no options market data available for CG Oncology, making it difficult to gauge investor sentiment through options pricing.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If CG Oncology beats expectations, history suggests a potential stock increase of around 0.10%, confirming a positive turnaround.
In-Line / Cautious
An in-line result may lead to a muted reaction, reflecting ongoing investor caution.
Miss
If the company misses expectations, history indicates a potential decline of around 0.83%, further eroding investor confidence.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026